This designation, which already was received in the European Union, allows XNK to advance clinical development of the drug. The company completed its first-in-human phase I/II clinical trial in multiple myeloma at the Karolinska University Hospital in Stockholm, Sweden, which showed the drug had a very good safety profile and promising efficacy data.

XNK plans to move ahead with clinical development of the drug candidate for multiple myeloma in Europe. The NK cell-based therapy was designed using XNK's closed manufacturing system.

Gracell secures funding to advance CAR T therapies
Gracell Biotechnologies has secured $100 million in series C funding to expand its chimeric antigen receptor (CAR) T-cell therapies.

Oncopeptides submits IND for peptide drug conjugate platform
Oncopeptides has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for OPD5, a second drug candidate based...

Glycostem gets orphan drug nod for multiple myeloma cell therapy
Glycostem Therapeutics has received orphan drug designation by the U.S. Food and Drug Administration for its off-the-shelf natural killer cell product...

Oncopeptides moves to file for regulatory approvals
Oncopeptides plans to submit an application for a conditional marketing authorization of melflufen in the European Union, based on the phase II Horizon...